Unexplained Ten Consecutive Early Third Trimester Intrauterine Fetal Deaths: A Diagnostic Dilemma

A Halder

Citation

Abstract
This report presents a case of unexplained ten consecutive early third trimester intrauterine fetal deaths in the absence of any maternal detectable risk factors and in presence of normal fetal growth. Detectable associations in tenth pregnancy were very low maternal serum alpha feto protein (<0.15 MOM MSAFP), turbid liquor amni and extensive placental pathology viz., fibrosis, hyalinization, infarction, narrowing as well as poor vascularization of chorionic vessels.

INTRODUCTION
Recurrent early third trimester fetal deaths may result from variety of causes like chronic maternal illness, Rh-isoimmunization, syphilis, uterine anomalies and chromosomal abnormality. Several reports also have indicated an association between recurrent fetal death with antiphospholipid antibodies, congenital protein C or protein S deficiency, activated protein C resistance, lupus anticoagulant, prothrombotic mutations, and disorders of maternal-placental interface, such as fetomaternal hemorrhage, as well as maternal floor infarction. In some cases primary placental pathology viz chorio-angiomas, primary avascularity of placenta, and chronic villitis of unknown origin has been implicated. However, universal acceptance of the later two associations are still lacking. We here report a case of ten consecutive early third trimester fetal losses with very low maternal serum alpha feto protein (<0.15 MOM MSAFP), turbid liquor amni and extensive placental pathology viz., fibrosis, hyalinization, infarction, narrowing as well as poor vascularization of chorionic vessels.

CASE REPORT
A macerated stillborn female fetus was referred for fetal autopsy. The fetus was delivered at 31 weeks of gestation to para ten, hindu, brahmin, middle class mother who had noticed decreased fetal movements three weeks prior to delivery and loss of fetal movement 4-5 days before the delivery. The mother was 32 years and father 38 years old at the time of birth of the child. There was no history of consanguinity. The present pregnancy had remained uncomplicated until decreased fetal movements were noticed around 27th week of pregnancy. At the onset of decrease in fetal movement an obstetric ultrasound was carried out privately that showed illsustained fetal breathing (at 27 weeks) and turbid liquor amni. All other fetal parameters were normal. Follow up ultrasound at the time of loss of fetal movement revealed fetal death at 30 weeks of gestation. Labour was induced by oxytocin infusion and a female fetus weighing 1.535 Kg was delivered vaginally. Autopsy findings revealed no intrauterine growth retardation (good subcutaneous fat and normal weight), no internal or external malformation & no umbilical cord pathology. However, thymus & placenta were hypoplastic and placenta was firm (nonspongy). Placental histopathology examination showed extensive placental fibrosis, hyalinization, infarction, narrowing as well as poorly vascularization of chorionic vessels (Fig.1 & 2).
Unexplained Ten Consecutive Early Third Trimester Intrauterine Fetal Deaths: A Diagnostic Dilemma

Figure 1

Figure 1: (X50 magnification) and Figure 2: (X125 magnification). Section of placenta showing fibrosis, hyalinisation, poor vascularisation and narrowing of vessel lumen.

Figure 2

Similar autopsy findings were reported in previous pregnancy. Almost similar obstetrics history had followed in previous pregnancies. The mother was under care of private obstetricians throughout most pregnancies and fetal death was unstoppable even after antiplatelet therapy in last pregnancy. All the fetuses were normal externally; seven were male and three were female. There were no signs of growth retardation in any of fetuses. The couple was investigated in detail in 10th pregnancy and also in the interval period between 9th & 10th pregnancy. The findings are summarised in Table 1. The mother was not known to have any chronic disease, however, she had two episodes of right sided hemiparesis at the age of 8 years and 14 years from which she had recovered fully.

Family history revealed no similar fetal losses. However, multiple sets of twin pregnancies were reported in first degree relatives of the couple (both sides).

DISCUSSION

Recurrent early third trimester fetal death may remain unexplained inspite of indepth investigation. The case which is described in this report is preferably termed as inadequately explained despite indepth investigations. As all her ten pregnancies ended in the same fashion and almost at the same period, we presume a common underlying etiopathologic factor. Our prime suspects are antiphospholipid like syndrome/antiphospholipid like syndrome and inherited thrombophilias (protein S deficiency, activated protein C resistance, prothrombotic mutations, etc). Primary antiphospholipid syndrome (APS) is unlikely in the absence of negative investigations (lupus anticoagulant, platelet count, VDRL test, complements and anticardiolipin antibody). However, adverse pregnancy outcome has been reported in patients with APS with low positive autoantibody titre as in our case. In addition Branch et al earlier reported that some patients with this history may produce antiphosphatidylserine antibody. Similarly, Tripplett et al reported that patient with APS may have positive reaction only against phosphatidylserine or phosphatidylinositol. Although testing for anticardiolipin antibody may provide some insight into patient with APS, testing for phosphatidylserine antibody identifies some rare patient who are non-reactive for anticardiolipin and lupus anticoagulant. Antiphospholipid like syndrome (in presence of absent autoantibodies) could be the possibility for the underlying cause and is supported by the history of recurrent transient ischemic attack (in the form of hemiparesis), pattern of recurrent fetal death after detection of fetal heart and placental histopathology viz. infarction, intravascular fibrin deposition and fibrosis although placental changes could be partly due to post mortem changes. Placental fibrosis is commonly seen with macerated stillbirth (long standing intrauterine death). However, it is very unlikely that placental histologic changes are solely postmortem as indirect evidences (low MSAFP, turbid liquor amni, decrease fetal movement 2-3 week before fetal death and thymic hypoplasia) indicate its antenatal onset. Very low maternal alpha feto protein can be seen with chromosomal abnormality (trisomy 21, trisomy 18, 48,XXYY and triploidy), placental chorioangiomas or placental fibrosis. Very low MSAFP levels with later condition can be explained by lack of transfer of AFP from fetus to mother because of placental fibrosis and hypovascularity. The
reason for turbid liquor is not apparent. However, it was not
due to oligohydramnios or amniotic infection or bleeding or
meconium in amniotic fluid. Placental fibrosis and
hypovascularity may probably the end result of chronic
villitis of immunologic origin through antiphospholipid or
antiphospholipid-like syndrome\textsuperscript{18}, activated protein C
resistance\textsubscript{6}, prothrombotic mutations\textsubscript{8}
and anti-annexin V autoantibodies\textsubscript{22}. Placental fibrosis may also be seen with
methyl parathion exposure\textsuperscript{23,24}, hyperthermia\textsubscript{25}, hypoxia\textsubscript{26,27}
and transforming growth factor-beta overactivity\textsubscript{26,28}.
Chronic hypoxia is unlikely to be the underlying cause
(commonly seen with pregnancy induced hypertension) as
this results in minimal fibrosis of the villi, whereas a marked
fibrosis with increase in stromal connective tissue and
villus vascularity results from thrombosis in main stem
and surface vessels\textsubscript{29} as seen with prothrombotic mutations\textsubscript{8}
and antiphospholipid syndrome\textsubscript{18}.
Possibilities like cogenital protein C deficiency, uterine
anomalies, balanced chromosomal translocation in parents,
etc were excluded by appropriate investigations (Table 1).
Similarly, monogenic, polygenic, multifactorial, uniparental
disomy and genomic imprinting as underlying cause is
unlikely as none recur in 100% offspring. Maternal floor
infarction or fetomaternal hemorrhage as cause is also
unlikely in the absence of high MSAFP\textsubscript{30}.

In conclusion we feel that evaluation of recurrent
unexplained fetal death is incomplete unless it directs
investigation towards detailed immunologic (beyond
anticardiolipin & lupus anticoagulant), inherited
thrombophilias as well as placental pathology. Time has
come to stress pathology of placenta as a factor in fetal
demise and not only as part of epiphenomena.

Figure 3
Table 1: Summary of Investigations

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Results During Non-Pregnancy Interval</th>
<th>Results During 9th &amp; 10th Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood group &amp; Type</td>
<td>B+ve</td>
<td>B+ve</td>
</tr>
<tr>
<td>Oxblood reference test</td>
<td>Normal</td>
<td>Not done</td>
</tr>
<tr>
<td>Email function test</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>TORCH Test</td>
<td>Positive</td>
<td>Not done</td>
</tr>
<tr>
<td>Listeria</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>α-Thalassemia Screening</td>
<td>Normal</td>
<td>Not done</td>
</tr>
<tr>
<td>Thyroid Function Test</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Ultrasonography</td>
<td>Normal uterus &amp; adnexa</td>
<td>Turbulent liquor after 2 weeks of pregnancy, hypercoagulability</td>
</tr>
<tr>
<td>Amniocentesis</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Anticardiolipin antibody</td>
<td>IgM (N-Epo 10 EU)</td>
<td>15.2, 7.1</td>
</tr>
<tr>
<td>Antiplatelet antibody</td>
<td>IgG (N-Epo 15 EU)</td>
<td>Normal</td>
</tr>
<tr>
<td>Complent C</td>
<td>Normal</td>
<td>17.7, 15.5</td>
</tr>
<tr>
<td>Complement C2</td>
<td>Negative</td>
<td>28.7, 21.5</td>
</tr>
<tr>
<td>Anti-microbial antibody</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-Annexin V</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-annexin V</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>Anti-annexin V</td>
<td>Positive</td>
<td>1:128</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>1:128</td>
</tr>
<tr>
<td>HLA typing</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>HLA typing</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>Anti-cardiolipin Ab</td>
<td>Positive</td>
<td>Positive</td>
</tr>
</tbody>
</table>

CORRESPONDENCE TO
Dr. Ashutosh Halder, Associate Professor, Department of
Reproductive Biology, All India Institute of Medical
Sciences, New Delhi 110029, India Phone: 011-26593304
ext. 4211 Mobile: 9313309579 Email:
ashutoshhalder@yahoo.co.in

References
Intrauterine death and circulatory anticoagulant
2. Harris EN, Charave AE and Hughes GR (1985) :
to cardiolipin as a predictor of fetal distress or death in
pregnant patients with systemic lupus erythematosus. N.
Engl. J. Med. 313; 152-156.
4. Trauscht-Van Horn JJ, Capeless EL, Easterling TR and
Bovill EG (1992) : Pregnancy loss and thrombosis with
protein C deficiency. Am. J. Obstet. Gynecol. 167 (4 pt 1);
968-972.
5. Tharakan T, Baxi LV and Diuguid D (1993) : Protein S
Gynecol. 168; 141-142.
Oehl G, Blumenfeld Z. Activated protein C resistance can be
associated with recurrent fetal loss. Br J Haematol. 1997; 97:
551-554.
7. Carreras LD, Perez GN, Vega HR, Casavilla F. Lupus
anticoagulant and recurrent fetal loss: successful treatment


Author Information
Ashutosh Halder, MD, DM
Associate Professor, Department of Reproductive Biology, All India Institute of Medical Sciences